25.09.2019
Board Meeting No 6 2019
Board Meeting No 6. September 25th 2019
12.08.2019
US Patent - Notice of Allowance
US patent - Notice of Allowance
23.07.2019
Canadian Patent - Notice of Allowance
Canadian Patent - Notice of Allowance
25.06.2019
Board Meeting No 5 2019
Board Meeting No 5. June 25th 2019
25.06.2019
Annual Report 2018
Regenics post a positive 2018 result of 1.72 mill NOK. 
13.06.2019
3D-bioprinting - ERA-NET BlueBio Joint Transnational Call 2019
BlueBio Joint Transnational Call 2019
08.05.2019
Board Meeting No 4 2019
Board Meeting No 4 2019, May 8th 2019
18.04.2019
Paragon Nordic AB - Collaboration
Paragon Nordic AB - Collaboration
13.03.2019
Patent annuities paid 2019
Regenics patents due for annuity/fee payments in May 2019 have been paid and continued by our patent legal consultant.
06.03.2019
Filing of additional Hong Kong patent application
The Patents registry of the Hong Kong Intellectual Property Department has verified receipt of Hong Kong Patent Application No. 16104205.5 from Regenics on January 25th 2019. The Hong Kong patent...
06.03.2019
Filing of new US provisional patent application
Filing of new US provisional patent application
28.02.2019
Board Meeting No 2 2019
March 5th 2019. 
23.01.2019
Regenics Board Meeting No 1 2019
January 23rd 2019.  
23.01.2019
Protocol Extraordinary Annual Meeting January 23rd 2019
January 23rd 2019 Protocoll of Extraordinary Annual Meeting January 23rd 2019. The Extraordinary Annual Meeting 2019 took place in the Companys office, Karvesvingen. 2, Oslo
18.12.2018
New EPO Patent granted 2018
New EPO patent
10.12.2018
Eqology AS launch Collagen Booster Serum
 An important commercial milestone has been reached for Regenics December 10th with the launch of the ground breaking EQ Collagen Boosting Serum from the Norwegian Direct Selling Company Eqology AS.  
30.11.2018
Protocol from Extraordinary Annual Meeting September 26th 2018
September 26th 2018 Protocol of Extraordinary Annual Meeting September 26th 2018. The Annual Meeting 2017 took place in the Companys office, Karvesvingen. 2, Oslo
29.11.2018
Notification of grant:Divisional EPO patent
Notification of grant: Divisional EPO patent
27.11.2018
Adam Robertson new Chief Scientific Officer in Regenics
 Adam Robertson has today signed up as  Chief Scientific Officer for Regenics AS.  Adam is part of the team that develops cutting  edge skin care and wound healing at Regenics.  Adam...
07.11.2018
Regenics Board Meeting No 4 2018
November 7th 2018
17.09.2018
Bernat Rocarols - R&D Engineer Regenics
   
09.09.2018
Regenics Board Meeting No 3 2018
September 9th 2018
19.08.2018
EPO National validation 2018
EPO Patent validation 
30.06.2018
Regenics Board Meeting No 2 2018
June 13th 2018

Page 1 of 5   >  >>

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.